MacroGenics (M55) Stock Overview

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. More details

M55 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 8.76% per year

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 12.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

M55 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

MacroGenics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for MacroGenics
Historical stock prices
Current Share Price	US$3.19
52 Week High	US$0
52 Week Low	US$0
Beta	1.2
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	M55	CH Biotechs	CH Market
7D	n/a	1.0%	2.2%
1Y	n/a	32.2%	10.7%

Return vs Industry: Insufficient data to determine how M55 performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how M55 performed against the Swiss Market.

Price Volatility

Is M55's price volatile compared to industry and market?
M55 volatility
M55 Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.7%
Market Average Movement	4.4%
10% most volatile stocks in CH Market	7.3%
10% least volatile stocks in CH Market	2.4%

Stable Share Price: M55's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine M55's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	293	Eric Risser	www.macrogenics.com

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.

MacroGenics, Inc. Fundamentals Summary

How do MacroGenics's earnings and revenue compare to its market cap?
M55 fundamental statistics
Market cap	CHF 200.55m
Earnings (TTM)	-CHF 56.06m
Revenue (TTM)	CHF 125.16m

1.6x

P/S Ratio

-3.6x

P/E Ratio

Is M55 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
M55 income statement (TTM)
Revenue	US$157.08m
Cost of Revenue	US$182.59m
Gross Profit	-US$25.50m
Other Expenses	US$44.85m
Earnings	-US$70.36m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.11
Gross Margin	-16.24%
Net Profit Margin	-44.79%
Debt/Equity Ratio	0%

How did M55 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/14 17:56
End of Day Share Price	2026/06/08 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MacroGenics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Peter Lawson	Barclays
Stephen V. Byrne	BofA Global Research

MacroGenics, Inc.BRSE:M55 Stock Report